Signifor (pasireotide) / Recordati - LARVOL DELTA

Etomidate, Ketoconazole, and Mitotane for Cushing Disease due to Adrenocortical Carcinoma (SCCM 2026) - "Triple therapy (carboplatin, etoposide, and doxorubicin) was considered but not initiated due to poor functional status...Osilodrostrat, mifepristone, metyrapone, and pasireotide were considered but restricted by primary disease and cost...EI's are safe and effective to reduce cortisol quickly, but many institutions and staff are unfamiliar with its use as a continuous infusion. Many challenges still exist for this difficult and rare disease."

Adrenal Cortex Carcinoma • Cushing’s Disease • Diabetes • Endocrine Disorders • Genito-urinary Cancer • Oncology • Rare Diseases • Solid Tumor

Anti-secretory and anti-proliferative actions of next-generation dual subtype 2 and 5 somatostatin receptor ligands in neuroendocrine tumor models. (PubMed, Front Oncol) - "The human insulinoma-derived NT-3 cell line and the murine AtT-20 corticotroph cell line, both expressing SSTR2 and SSTR5, were treated with 1-50 nM of the novel SRLs or reference agents (octreotide, pasireotide)...Dual SSTR2/SSTR5 agonists exhibit antisecretory and antiproliferative activity in NET models that was similar or even superior to reference SRLs. These findings support their further development as next-generation SRLs for SSTR2/5-expressing tumors."

Journal • Preclinical • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor • SSTR • SSTR2 • SSTR5

Somatostatin and its analogs in the management of postoperative pancreatic fistulas: A comprehensive review. (PubMed, World J Gastrointest Surg) - "The somatostatin analogs include octreotide, lanreotide, and pasireotide...Ongoing research should aim to clarify the best patient selection. Additionally, it should have the goal of not only being economically beneficial but also being integrated into treatment based on somatostatin for the most precise preoperative care."

Journal • Review

Case Report: Paradoxical responses to pasireotide in a patient with a silent corticotroph adenoma that transformed into an ACTH-secreting adenoma. (PubMed, Front Oncol) - "Pasireotide LAR successfully reduced the tumor mass despite paradoxical responses. A transient increase in hypercortisolemia after pasireotide LAR was difficult to predict but was managed with steroidogenesis inhibitors."

Journal • Cushing’s Disease • Endocrine Disorders • Oncology

SOM230-RECAG-PK-612: Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects. (clinicaltrialsregister.eu) - P1 | N=40 | Not yet recruiting | Sponsor: Recordati AG

New P1 trial • Hypoglycemia

PASIPHY_PEN: Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: RECORDATI GROUP | Recruiting ➔ Completed

Trial completion

Histological Evidence of familial GH-PitNET Associated with Germline MAX Mutation. (PubMed, Eur J Endocrinol) - "Despite multimodal therapy (lanreotide, cabergoline, two debulking surgeries), disease control was achieved only after pasireotide and adjuvant proton therapy. The same variant was found in her father, who had a smaller intrasellar macroadenoma causing acromegaly. This familial observation provides the functional evidence that MAX is a driver in GH-PitNET and a candidate gene for PitNET predisposition."

Journal • Acromegaly • Endocrine Disorders • Neuroendocrine Tumor • Oncology • Solid Tumor • MAX

Cost-effectiveness of pasireotide long-acting release in acromegaly: a systematic literature review and methodology assessment. (PubMed, J Med Econ) - "Evidence on pasireotide LAR's cost-effectiveness versus pegvisomant regimens remains inconclusive. Although two studies indicated that pegvisomant is more cost-effective, the study with the highest methodological credibility found that pasireotide LAR is a cost-effective alternative."

HEOR • Journal • Review • Acromegaly • Endocrine Disorders • SSTR

Update and practical recommendations for the use of medical treatment of Cushing´s syndrome. (PubMed, Endocr Rev) - "Currently available medical treatments include adrenal steroidogenesis inhibitors that block cortisol secretion (ketoconazole, levoketoconazole, metyrapone, osilodrostat, mitotane, and etomidate), drugs that modulate pituitary ACTH secretion (pasireotide and cabergoline), and drugs that block peripheral glucocorticoid receptors (mifepristone). In this review, we summarize the main indications for medical treatment in CS, the mechanism of drug action, efficacy, recommended doses, and safety of the currently available drugs, as well as potential future treatments. We also discuss titration and block-and-replace approaches for control of hypercortisolism and provide recommendations for the use and monitoring of medical treatment in CS, including patients with endogenous hypercortisolism in special situations such as pregnancy, cyclic CS and mild autonomous cortisol secretion."

Journal • Cushing’s Disease • Endocrine Disorders

PASIPHY_PEN: Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: RECORDATI GROUP

New P1 trial

The effect of hypercortisolism treatment on dyslipidemia in Cushing syndrome: systematic review and meta-analysis. (PubMed, J Clin Endocrinol Metab) - "Our study demonstrate a significant improvement in serum lipid levels after treatment of CS. Since the cardiovascular complications of hypercortisolism depend on several factors, further studies are needed to determine whether this directly translates into an adequate reduction in the risk of major cardiovascular events."

Journal • Retrospective data • Cardiovascular • Cushing’s Disease • Dyslipidemia • Endocrine Disorders • Metabolic Disorders

Real-life data on pasireotide in monotherapy or combined in active Cushing's disease. (PubMed, Front Endocrinol (Lausanne)) - "This is a retrospective monocentric study evaluating the real-life efficacy and safety of pasireotide alone or when combined with cabergoline or metyrapone. This is the first study to report metyrapone add-on to pasireotide, but larger studies are needed to further investigate this association. Pasireotide surely worsens glucose homeostasis, but its positive effects, alone or combined, on blood pressure, lipid profile, and body weight justify its use under careful hyperglycemia management."

Journal • Monotherapy • Retrospective data • Cardiovascular • Cushing’s Disease • Diabetes • Endocrine Disorders

Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar. (PubMed, Case Rep Endocrinol) - "Patient 2, 48-year-old male with a significant macroadenoma and prior cabergoline treatment, achieved partial biochemical control. Four out of these five patients showed reduction in tumour size. This case series corroborates the findings from previous studies, adding insight into treatment challenges and benefits experienced by this heterogeneous group of patients on pasireotide."

Journal • Acromegaly • Diabetes • Endocrine Disorders • Metabolic Disorders • Oncology • Pituitary Gland Carcinoma • Type 2 Diabetes Mellitus • IGF1 • SSTR

A Case of Adrenocorticotropin-dependent Cushing Syndrome with Osilodrostat Exposure in Early Pregnancy. (PubMed, JCEM Case Rep) - "After a relapse at 35 years of age, she was initially treated with metyrapone but switched to osilodrostat and hydrocortisone because of nausea, achieving reasonable cortisol control. This case prompts consideration of whether osilodrostat can be used during pregnancy if risks are justified. Pasireotide is rarely used in pregnancy and may have limited effectiveness, but when given, can cause hyperglycemia because of insulin and incretin suppression and should be monitored carefully."

Journal • Cushing’s Disease • Diabetes • Endocrine Disorders • Infectious Disease • Nephrology • Novel Coronavirus Disease • Oncology • Pituitary Gland Carcinoma • Renal Disease

Immunohistochemical analysis of filamin a expression in acromegaly and its correlation with tumor characteristics and treatment response. (PubMed, Sci Rep) - "In conclusion, our results suggest that FLNA may be associated with tumor invasiveness in GH-secreting pituitary tumors. While data on Pasireotide-treated patients are exploratory, further studies are needed to assess FLNA's potential as a treatment response marker in acromegaly."

Journal • Acromegaly • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • CDH1 • FLNA • SSTR • SSTR2 • SSTR5

Case Report: Bilateral lens dislocation as an atypical presentation of acromegaly and review of the ocular effects of GH/IGF-1 excess. (PubMed, Front Endocrinol (Lausanne)) - "It may indicate advanced disease and, if confirmed in other cohorts, could be considered among the suggestive signs of acromegaly. In our case, the use of pasireotide allowed adherence to therapy and optimal therapeutic response in a multicomplicated, non-self-sufficient patient."

Journal • Acromegaly • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diabetes • Endocrine Disorders • Heart Failure • Hypertension • Metabolic Disorders • Osteoporosis • Pituitary Gland Carcinoma • Pulmonary Arterial Hypertension • Rheumatology • Type 2 Diabetes Mellitus • IGF1

Dual Inhibitors of c-MET and EGFR in Triple Negative Breast Cancer: Pharmacophore Modeling and Molecular Dynamics Based in Silico Drug Repositioning. (PubMed, Iran J Pharm Res) - "Considering pasireotide's potential to target c-MET and EGFR pathways, our findings provide a strong rationale for its further preclinical validation in the treatment of TNBC. The demonstrated efficacy and safety of pasireotide in this aggressive subtype of cancer can now be evaluated through subsequent studies."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • EGFR • MET

Acromegaly treatment and bone: a bidirectional relationship. (PubMed, Pituitary) - "Recent studies have shown that first- and second-generation somatostatin receptor ligands (SRLs) can reduce the incidence of vertebral fractures (i-VFs). However, a direct effect of these molecules on bone metabolism has not yet been reported. Aims: This review summarizes the results of studies investigating the frequency of i-VFs according to different GH/IGF-I-lowering drugs and the potential effects of these treatments on bone metabolism, as well as preclinical data on potential molecular pathways that interact between GH/IGF-I-lowering drugs and bone metabolism."

Journal • Review • Acromegaly • Endocrine Disorders • Musculoskeletal Diseases • Neuroendocrine Tumor • Oncology • Orthopedics • Rare Diseases • Solid Tumor • IGF1 • SSTR

Growth hormone in disease and treatment (Review). (PubMed, Med Int (Lond)) - "Furthermore, it summarizes recent findings on the protective effects of GHRHAnts and FDA-approved SSAs, such as octreotide, lanreotide and pasireotide, in GH-related and endothelium-dependent dysfunctions. Based on the provided bibliography, an emerging body of evidence suggests that GH modulators may represent a promising therapeutic possibility towards blood brain barrier dysregulation, keratitis, direct and indirect lung injury, sepsis, and acute respiratory distress syndrome."

Journal • Review • Acromegaly • Acute Lung Injury • Acute Respiratory Distress Syndrome • Endocrine Disorders • Infectious Disease • Inflammation • Keratitis • Ocular Inflammation • Oncology • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Septic Shock

Somatostatin Ameliorates Corneal Nerve Abnormalities and Inflammation Through Regulation of Macrophage Activities in Dry Eye Disease. (PubMed, Invest Ophthalmol Vis Sci) - "SOM230 alleviates nerve abnormalities in DED by suppressing inflammatory pathways (TNF-α, NF-κB) and promoting a shift in macrophage polarization from the pro-inflammatory M1 phenotype to the reparative M2 phenotype. These findings suggest that modulation of macrophage polarization is a crucial mechanism underlying the therapeutic effects of SOM230, highlighting its potential as a treatment strategy for nerve damage in DED."

Journal • Dry Eye Disease • Inflammation • Keratitis • Ocular Inflammation • Ophthalmology • Pain • TNFA

Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas? (PubMed, Pituitary) - "In a subgroup, pasireotide inhibited prolactin secretion with comparable potency to cabergoline. Targeting SST5 with pasireotide may be a potential treatment modality for further clinical investigation in the treatment of a subset of DA resistant or intolerant prolactinomas."

Journal • PRL

Comparative Effectiveness and Safety of Prophylactic Drugs in Preventing Clinically Relevant Postoperative Pancreatic Fistula After Pancreatic Resection: A Network Meta-Analysis of RCTs (ACG 2025) - "A total of 2,782 records were screened, with 17 studies meeting inclusion criteria, comprising 2,850 patients (1,411 treatment; 1,439 control). Patient distribution included 80 hydrocortisone, 369 octreotide, 410 pasireotide, 1,376 placebo, and 137 somatostatin recipients. Somatostatin showed the greatest reduction in overall postoperative pancreatic fistula (POPF) risk (OR 0.40; 95% CI, 0.16–0.97), followed by octreotide (OR 0.55; 95% CI, 0.37–0.82), hydrocortisone (OR 0.91; 95% CI, 0.29–2.83), while pasireotide demonstrated no significant benefit (OR 1.06; 95% CI, 0.55–2.05)."

HEOR • Retrospective data • Novel Coronavirus Disease

Five-year survival outcomes following perioperative hydrocortisone versus pasireotide in patients with high risk of pancreatic fistula: Secondary analysis of the HYPAR randomized clinical trial. (PubMed, Scand J Surg) - No abstract available

Clinical • Journal

Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies. (PubMed, Diabetol Metab Syndr) - "Pharmacologic management of PBH shows promise with agents such as anakinra, empagliflozin, pasireotide, and acarbose. However, given the considerable heterogeneity, small sample sizes, and wide confidence intervals, very low quality of effect estimates, and varied definitions of PBH, these pooled estimates should be considered hypothesis-generating only, and not confirmatory. There is an urgent need for standardized PBH definitions, patient-centered outcome measures, longer follow-up, and adequately powered RCTs to establish evidence-based therapeutic guidelines."

Clinical • Journal • Hypoglycemia

Management of patients with Cushing's disease in the Gulf Region: a Delphi consensus recommendation. (PubMed, Front Endocrinol (Lausanne)) - "For persistent/recurrent disease, repeat surgery was favored when feasible (91.3%), while medical therapy (e.g., pasireotide or steroidogenesis inhibitors) was preferred for inoperable cases...The study provides structured, region-specific recommendations for CD management in the Gulf region, emphasizing surgical intervention where feasible, tailored medical therapy, and careful monitoring. These guidelines aim to standardize care, address resource limitations, and improve patient outcomes."

Journal • Cushing’s Disease • Endocrine Disorders • Pituitary Gland Carcinoma